Telehealth ADHD Prescribing: What Prescribers Can Do

If you’re a psychiatrist or PMHNP considering telehealth ADHD care, you’ve probably asked yourself: Can I legally prescribe Adderall through a video visit? What about state-by-state differences? And is this financially viable compared to traditional practice?

The short answer: Yes, psychiatrists can prescribe ADHD medications via telehealth in 2026 — but the landscape is more nuanced than it was during the pandemic’s peak. Federal flexibilities that made remote stimulant prescribing possible are currently extended through the end of 2025, with 2026’s rules still uncertain. State regulations add another layer, especially for PMHNPs whose prescribing authority varies dramatically depending on where they practice.

This guide breaks down everything you need to know about telehealth ADHD prescribing: current federal rules, state-by-state scope of practice differences, reimbursement realities, and how platforms like Klarity Health remove the guesswork (and the marketing gamble) from building a telehealth ADHD practice.

The Federal Framework: Where Telehealth ADHD Prescribing Stands Now

The Ryan Haight Act and COVID-Era Waivers

Before COVID-19, the Ryan Haight Act (2008) required at least one in-person medical evaluation before any provider could prescribe Schedule II controlled substances — including ADHD stimulants like Adderall, Vyvanse, or Ritalin — via telemedicine. This effectively blocked virtual-only ADHD care.

The pandemic changed everything. The DEA issued emergency waivers allowing providers to initiate stimulant prescriptions entirely through telehealth without that in-person visit. These flexibilities have been extended multiple times; most recently, the DEA and HHS extended the waiver through December 31, 2025.

What happens in 2026? As of February 2026, there’s no permanent rule in place. Congress and the DEA have been deliberating on whether to make these flexibilities permanent, create a new ‘special registration’ for telehealth prescribers, or let the Ryan Haight Act’s original in-person requirement return. For now, psychiatrists can continue prescribing stimulants to new telehealth patients under the existing extension — but you should monitor DEA announcements closely and have contingency plans (like partnering with local clinics for in-person exams) if regulations tighten.

What Psychiatrists Can Do Right Now

Psychiatrists (MD/DO) operating under current federal rules can:

• Conduct comprehensive ADHD evaluations via video
• Diagnose ADHD based on clinical interview, rating scales, and collateral information
• E-prescribe Schedule II stimulants (Adderall, Vyvanse, Ritalin, etc.) for new patients entirely through telehealth
• Manage ongoing medication adjustments and monthly follow-ups remotely
• Prescribe non-stimulant ADHD medications (atomoxetine, bupropion, guanfacine) without additional restrictions

Key requirements:

• Use a DEA-compliant e-prescribing platform with two-factor authentication
• Check your state’s Prescription Drug Monitoring Program (PDMP) before prescribing controlled substances (required in most states)
• Document thorough evaluations that meet standard-of-care criteria
• Ensure patients are located in states where you hold an active medical license

The clinical work is entirely feasible via telemedicine. ADHD diagnosis relies on history, behavioral assessment, and rating scales — all of which can be administered remotely. Physical exam needs are minimal (you might ask patients to monitor their own blood pressure and heart rate given stimulants’ cardiovascular effects, which many do with home devices or pharmacy kiosks).

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Prescribing Rules: Where Scope of Practice Gets Complicated

While federal law sets the baseline for controlled substance prescribing, state medical boards and nurse practice acts determine who can prescribe and under what supervision. This is where things diverge sharply — especially for PMHNPs.

Psychiatrists: Universal Authority (With State Licensing Caveats)

Psychiatrists face no state-level scope restrictions on prescribing ADHD medications. Your MD/DO license gives you full prescriptive authority in every state where you’re licensed. The only variables are:

• State-specific telehealth rules: A few states add their own controlled substance prescribing requirements (but most defer to federal law)
• PDMP checking mandates: States like New York require you to check the prescription monitoring database for every controlled substance prescription; others require checks every 90 days or before initial prescriptions
• Telehealth modality requirements: Some states (like Texas) require video for controlled substance prescribing — audio-only calls won’t cut it

Example — Florida: Florida explicitly permits telehealth prescribing of Schedule II stimulants when treating psychiatric disorders. The state law carved out mental health treatment from broader telehealth controlled-substance restrictions, making Florida one of the most permissive states for tele-ADHD care.

Example — Texas: Texas allows telehealth prescribing of controlled substances for mental health conditions via live video (but not for chronic pain management, which has stricter in-person requirements). No additional state barriers beyond federal law — but remember, Texas has severe psychiatrist shortages (about 1 psychiatrist per 9,000 residents), so demand far outstrips supply.

PMHNPs: Authority Depends Entirely on Your State

This is where scope of practice becomes a real headache. Nurse practitioners’ ability to prescribe ADHD stimulants varies from full independence to outright prohibition, depending on state law.

Full Practice Authority States (NPs can prescribe stimulants independently after meeting experience requirements):

New York:

• NPs must complete 3,600 supervised hours (about 2 years) with a collaborating physician
• After that, full independent practice — including Schedule II prescribing — with no ongoing physician oversight
• No quantity limits or special restrictions on stimulants
• Must check PDMP for every controlled prescription and use e-prescribing statewide

Illinois:

• NPs can obtain Full Practice Authority after 4,000 hours of clinical experience + 250 hours of continuing education
• Once granted, NPs prescribe all medications independently (including Schedule II stimulants for ADHD)
• Prior to FPA, NPs need a written collaborative agreement; the collaborating physician must explicitly delegate Schedule II authority
• Illinois requires a mid-level controlled substance license and DEA registration for NP prescribing

California (transitioning):

• AB 890 created a pathway for experienced NPs (≥3 years, 4,600 hours) to become independent ‘104 NPs’ starting in 2023
• Until then, NPs (‘103 NPs’) require physician supervision in healthcare settings
• NPs must complete a pharmacology course specific to Schedule II drugs to prescribe stimulants
• By 2026, many experienced California PMHNPs have achieved independence; newer NPs still need collaborators

Restricted Practice States (NPs require physician collaboration AND face additional limits):

Texas:

• All NPs require a Prescriptive Authority Agreement with a supervising physician
• Critical restriction: NPs cannot prescribe Schedule II controlled substances for outpatient care except in hospitals (≥24 hours inpatient), emergency departments, or hospice settings
• Translation: A Texas NP cannot write an Adderall prescription for a routine ADHD patient at home — only a physician can
• This effectively sidelines PMHNPs from ADHD medication management in Texas unless they work alongside an MD who handles all stimulant prescriptions

Florida:

• PMHNPs require a written supervisory protocol with a psychiatrist (not just any physician — must be a psychiatrist)
• General rule: APRNs limited to 7-day supplies of Schedule II drugs
• Exception: ‘Psychiatric nurses’ (PMHNPs with master’s+ working under a psychiatrist’s protocol) are exempt from the 7-day limit when prescribing psychotropic medications for mental health disorders
• In practice: Florida PMHNPs can prescribe 30-day supplies of Adderall for ADHD patients, but they cannot practice independently — they must collaborate with a psychiatrist

Pennsylvania:

• NPs require a collaborative agreement with a physician (no independent practice)
• Initial Schedule II prescription: NPs limited to 72-hour supply and must notify the collaborating physician within 24 hours
• Ongoing therapy: NPs can prescribe up to 30-day supplies of Schedule II medications, but the collaborating physician must re-evaluate the patient before extending treatment beyond 30 days
• One physician can collaborate with up to 4 NPs
• In ADHD practices, many workflows have the psychiatrist write the initial stimulant prescription (bypassing the 72-hour limit), then the NP handles monthly refills

The Practical Impact: Who Can Build a Solo Telehealth ADHD Practice?

If you’re a psychiatrist: You can build a telehealth ADHD practice in any state where you hold a license. Your only constraints are federal telehealth rules (currently permissive through 2025) and ensuring you meet standard-of-care documentation requirements.

If you’re a PMHNP:

• In New York, Illinois, or California (post-experience): You can manage ADHD patients independently once you’ve met your state’s FPA requirements — essentially practicing at the same level as a psychiatrist
• In Florida or Pennsylvania: You can treat ADHD patients, but you’ll need a collaborating psychiatrist. Florida allows you to prescribe standard 30-day stimulant supplies under supervision; Pennsylvania’s 72-hour initial limit means tighter coordination with your collaborator
• In Texas: You’re effectively locked out of prescribing stimulants for outpatient ADHD unless you’re in a hospital setting. Texas NPs typically handle therapy, care coordination, or non-stimulant medication management while an MD manages stimulant prescriptions

For telehealth platforms: This is why many national services either focus on recruiting psychiatrists (who can practice across all states without supervision) or build state-specific collaborating physician networks for PMHNPs in restricted states.

Reimbursement: Is Telehealth ADHD Care Financially Sustainable?

One of the biggest questions providers ask: Will I actually get paid appropriately for virtual ADHD visits?

Telehealth Payment Parity: Nearly Universal in 2026

The good news: Telehealth reimbursement parity is standard practice across most payers and states. By 2026, approximately 48 states have enacted telehealth parity laws or policies, meaning private insurers must pay the same rate for virtual visits as in-person visits for mental health services.

Medicare:

• Extended telehealth coverage for mental health services through at least 2024 (with further extensions likely)
• Pays telehealth psychiatric visits at the non-facility fee schedule rate — the same as in-person
• Reimbursement for common ADHD medication management codes:
• 99213 (15-minute established patient visit): ~$89–95
• 99214 (25-minute moderate complexity visit): ~$125–136
• 90792 (initial psychiatric diagnostic evaluation): ~$188–202

Commercial Insurance:

• Typically pays equal to or higher than Medicare for psychiatric services
• Many plans reimburse 10–30% above Medicare rates, though this varies by insurer and contract
• Psychiatrists generally receive the highest reimbursement rates for medication management compared to other provider types

Medicaid:

• Pays substantially less than Medicare (often 50% or less)
• Typical Medicaid rates: ~$41 for a 15-minute med check (99213), ~$64 for 25 minutes (99214)
• However, Medicaid programs in most states now cover telepsychiatry at parity and have made many COVID-era telehealth flexibilities permanent

The Economics: What Does a Full Telehealth Schedule Look Like?

Let’s be realistic about the math. If you’re conducting four 15-minute medication management visits per hour:

• Medicare patients: 4 visits × $90 (99213) = $360/hour gross
• Commercial insurance patients: 4 visits × $110–130 (typical private rate) = $440–520/hour gross
• Mix of payers (Medicare, commercial, some Medicaid): Likely averaging $380–450/hour gross

Compare this to traditional in-office practice where overhead (rent, staff, billing, etc.) can consume 50–60% of revenue. With telehealth:

• No office rent
• Minimal overhead (platform fees, malpractice, licensing)
• No commute or geographic limitations
• Ability to fill gaps in your schedule more easily (patients can book around your availability across time zones)

The catch: You need patient volume. Which brings us to the biggest hidden cost…

The Real Cost of Patient Acquisition: Why DIY Marketing Rarely Makes Financial Sense

Here’s what most articles won’t tell you about building a telehealth practice: acquiring qualified psychiatric patients is expensive and time-consuming.

The True Cost of DIY Patient Acquisition

When providers think about going independent with telehealth, they often underestimate patient acquisition costs. Let’s break down what it actually takes:

Google Ads / PPC:

• Mental health keywords cost $15–40+ per click
• Conversion rates from click to booked appointment: typically 2–5%
• Realistic cost per booked patient: $200–400+
• And that’s after months of testing campaigns, optimizing landing pages, and throwing money at clicks that don’t convert

SEO (Organic Search):

• Takes 6–12 months of consistent investment before generating meaningful patient flow
• Requires ongoing content creation, technical optimization, and link building
• Monthly cost (agency + content + technical work): $2,000–5,000+
• Most solo providers lack the expertise or patience to see it through

Directory Listings (Psychology Today, Zocdoc):

• Monthly subscription fees: $30–100+ per directory
• You’re competing with hundreds of other providers on the same page
• Zocdoc charges $35–100+ per booking on top of monthly fees
• Total monthly cost including subscriptions can easily hit $500–1,500+

Social Media / Content Marketing:

• Time-intensive (hours per week creating content)
• Requires consistency over months to build audience
• If outsourced: $1,000–3,000+/month for social management
• ROI is unpredictable and slow

Add it all up:If you’re spending $3,000–5,000/month on marketing across channels, and you acquire 10–15 new patients per month, your true patient acquisition cost is $200–500 per patient. And that’s if your campaigns are working — many providers burn through thousands testing strategies that never deliver consistent results.

The Klarity Model: Pay Only When You See Patients

This is where a platform like Klarity Health fundamentally changes the economics.

Instead of gambling on marketing channels with uncertain ROI, Klarity uses a pay-per-appointment model:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no need for separate platform subscriptions)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

The business case:Rather than spending $3,000–5,000/month on marketing with unpredictable results, you pay a standard listing fee per new patient appointment. That’s guaranteed ROI — you only pay when you’re already earning from the visit.

For most providers, especially those starting out or scaling their practice, removing patient acquisition risk entirely is the difference between a sustainable telehealth practice and one that bleeds money for months before gaining traction.

Clinical Workflows: How ADHD Medication Management Actually Works via Telehealth

Let’s get practical. What does a typical telehealth ADHD visit look like, and how do you ensure you’re practicing safely and compliantly?

Initial Evaluation (45–60 minutes)

Pre-visit preparation:

• Patient completes intake forms and ADHD rating scales electronically (ASRS for adults, Vanderbilt or Conners for children/adolescents)
• Review prior records if available (previous diagnoses, medication trials, psychiatric history)
• Check state PDMP for any controlled substance history

The video visit:

• Comprehensive psychiatric interview covering:
• Current symptoms (inattention, hyperactivity, impulsivity) and functional impairment
• Onset and course (ADHD is a lifelong condition — symptoms should trace back to childhood)
• Rule out other causes (anxiety, depression, sleep disorders, substance use)
• Collateral information (for kids: teacher reports, parent observations; for adults: work performance, relationship impacts)
• Mental status examination via video (observation of attention, impulse control, fidgeting)
• Discussion of treatment options (stimulants vs non-stimulants, behavioral strategies, therapy referrals)
• If prescribing stimulants: obtain informed consent covering risks (cardiovascular effects, abuse potential, side effects)
• Document baseline vitals (patient self-reports blood pressure and heart rate, or you request they obtain from a recent PCP visit or pharmacy check)

Prescribing:

• E-prescribe via DEA-compliant platform (two-factor authentication required)
• For states requiring video (like Texas): ensure documentation notes ‘live video telemedicine visit conducted, patient located in [state]’
• PDMP check completed and documented
• Typical initial prescription: start low (e.g., Adderall 5–10mg daily or Vyvanse 20–30mg) with plan for titration

Coding: 90792 (psychiatric diagnostic evaluation) — Medicare reimburses ~$188–202, commercial often higher

Follow-Up Visits (10–20 minutes, typically monthly)

Stimulant prescriptions are typically written for 30-day supplies (no refills allowed on Schedule II), so monthly follow-ups are standard practice for ADHD medication management.

Visit structure:

• Review symptom control (using brief rating scales or clinical interview)
• Assess side effects (appetite, sleep, blood pressure, mood)
• Check adherence and any signs of misuse (if concerns arise, some providers use urine drug screens)
• Adjust dose as needed (titrate up if symptoms persist, reduce if side effects problematic)
• Re-prescribe for next 30 days (PDMP check if required by state law or practice policy — at least quarterly is common)

Coding: 99213 or 99214 depending on complexity — Medicare reimburses ~$89–136

Efficiency tip: With telehealth, you can structure your day with back-to-back 15-minute slots. Patients appreciate the convenience (no commute, easier to schedule during lunch breaks), and no-shows tend to be lower than in-person practices since there’s less friction.

Managing Medication Shortages (A Current Reality)

Since late 2022, ADHD medication shortages — particularly Adderall and generic amphetamine salts — have been widespread. The DEA increased production quotas in 2024 to address this, but many pharmacies still face intermittent supply issues.

How to handle this in telehealth practice:

• Educate patients upfront that shortages exist (set expectations early)
• Have backup options ready: alternative stimulants (methylphenidate vs amphetamine), non-stimulants (atomoxetine, guanfacine, bupropion)
• Partner with multiple pharmacies if possible, or help patients identify pharmacies with stock
• Document medication switches in the chart (insurance prior auths may be needed for brand-name alternatives)

This is an area where telehealth actually helps — you can often coordinate with patients’ local pharmacies more flexibly than in a traditional office setting, and you’re not limited to a single geographic area’s pharmacy network.

Compliance and Risk Management: Avoiding the ‘Online Pill Mill’ Perception

High-profile cases of telehealth companies overprescribing stimulants have put regulatory scrutiny on ADHD telemedicine. In 2023, investigations revealed some platforms were prescribing Schedule II controlled substances after brief, superficial evaluations — sometimes via text-based assessments without video exams.

How to protect yourself and practice safely:

1. Document thoroughly:

• Your evaluation should mirror what you’d do in-person: comprehensive history, DSM-5 diagnostic criteria met, differential diagnosis considered
• Document PDMP checks, informed consent, and any collateral information
• Many state medical boards have issued guidance that ‘telehealth standard of care = in-person standard of care’ — your documentation should reflect that

2. Verify patient identity and location:

• Confirm the patient’s identity at each visit (visual ID check via video)
• Document the state where the patient is located (you must be licensed there)
• This protects you if there are questions about jurisdiction or cross-state prescribing

3. Use clinical judgment on high-risk cases:

• Red flags: patient requesting specific stimulants by name, history of substance misuse, inconsistent story, ‘doctor shopping’ patterns on PDMP
• When in doubt: start with non-stimulants, require collateral information, or refer for in-person evaluation
• Some providers include urine drug screens for patients with substance use history

4. Schedule regular follow-ups:

• Monthly visits are standard for stimulant therapy (aligns with 30-day prescription limits)
• Regular contact allows you to monitor for misuse, diversion, or emerging complications

5. Coordinate with other providers:

• If treating a child/adolescent, loop in parents, school counselors, or pediatricians
• For adults with complex comorbidities, communicate with primary care or therapists
• This demonstrates comprehensive care and reduces isolation of telehealth practice

State-specific compliance:

• Florida: Requires telehealth providers to practice consistent with in-person standard of care by statute
• Texas: Medical board has been particularly vigilant about inappropriate telehealth prescribing (influenced by 2023 legislative concerns about stimulant overprescribing)
• New York: Mandatory PDMP check for every controlled prescription (not just first prescription)

Why State Licensing Matters (And How to Think About Multi-State Practice)

One question that comes up constantly: Can I treat patients in multiple states via telehealth?

The rule: You must hold an active medical license (or APRN license) in every state where your patients are located at the time of the telehealth visit. There are no shortcuts.

Interstate Medical Licensure Compact (IMLC)

For physicians, the IMLC streamlines getting licensed in multiple states. Currently 40 states participate (including Pennsylvania, Illinois, and soon Texas). Benefits:

• Apply once through your home state
• Receive expedited licensure in other IMLC states (typically weeks instead of months)
• Lower administrative burden than applying to each state individually

California, New York, and Florida are not IMLC members as of 2026, so you’ll need to apply to those states individually if you want to treat patients there.

APRN Compact (For NPs)

There’s also an Advanced Practice Registered Nurse Compact (APRN Compact), but adoption has been slower. As of 2026, fewer than 15 states participate, and major states like California, Texas, New York, Florida are not members. Most PMHNPs still need to obtain individual state licenses for multi-state telehealth practice.

Strategic Licensing Decisions

If you’re building a telehealth practice:

• Start with your home state (where you already have a license)
• Consider adding high-demand states with large populations: California, Texas, Florida, New York together represent over 100 million people and have significant psychiatrist shortages
• Factor in licensing costs (initial fees range from $200–800 per state, plus renewal fees every 1–3 years) and CME requirements (which vary by state)
• Consider compact states if you want to scale quickly across regions (IMLC for MDs makes this much easier)

For platforms like Klarity:One major advantage is that the platform can match you with patients in states where you’re already licensed, and help guide you on strategic licensing decisions based on where demand is highest and your practice goals.

State-by-State Quick Reference: ADHD Prescribing Rules for Priority States

FAQ: Common Questions About Telehealth ADHD Prescribing

Q: Can I prescribe Adderall to a patient I’ve never met in person?

A: Yes, under current federal rules (extended through the end of 2025). The DEA’s COVID-era waiver allows psychiatrists to initiate Schedule II stimulant prescriptions entirely via telehealth without an initial in-person exam. However, this is a temporary extension — monitor DEA announcements for 2026 policy changes.

Q: What happens if the federal telehealth flexibility expires?

A: If the Ryan Haight Act’s original in-person requirement returns, you would need to conduct at least one in-person medical evaluation before prescribing controlled substances to new patients via telemedicine. Some providers are preparing by partnering with local clinics or urgent care centers to handle in-person exams if needed. Established patients (those you’ve already seen via telehealth) would likely be grandfathered under existing relationships.

Q: Do I need a DEA registration in every state where I prescribe?

A: You need one DEA registration tied to your practice address (typically your home state). That DEA number is valid for prescribing controlled substances to patients in any state where you hold a medical license. You don’t need separate DEA registrations for each state (unless you maintain physical practice locations in multiple states).

Q: How do I handle prior authorizations for ADHD medications?

A: Prior auths are common for brand-name stimulants (Vyvanse, Adderall XR) and some non-stimulants. Most telehealth platforms include prior auth support as part of their service, or you’ll need staff/service to handle the paperwork. Generic stimulants (immediate-release amphetamine salts, methylphenidate) typically require fewer prior auths.

Q: Can PMHNPs in restricted states still build telehealth ADHD practices?

A: Yes, but you’ll need a collaborating psychiatrist. In states like Florida or Pennsylvania, many telehealth platforms provide physician collaborators as part of the service. In Texas, the NP role is more limited to non-stimulant management or therapy unless paired very closely with an MD who handles all stimulant prescriptions.

Q: Is cash-pay ADHD care viable, or do I need to take insurance?

A: Both models work. Cash-pay telehealth ADHD services typically charge $150–300 for initial evaluations and $75–150 for follow-ups. Some patients prefer this for privacy or convenience. However, taking insurance expands your patient base significantly — many people with ADHD can’t afford consistent out-of-pocket care, and insurance reimbursement rates (especially for psychiatrists) are solid with telehealth parity.

Q: What’s the difference between working solo vs joining a platform like Klarity?

A: Solo practice: You control everything (schedule, fees, patient selection) but you handle all patient acquisition costs, marketing, billing, credentialing, platform technology, and compliance infrastructure. Realistic startup timeline: 6–12 months before consistent patient flow.

Platform model (Klarity): You focus on clinical care while the platform handles patient acquisition, credentialing, billing, telehealth technology, and compliance. Pay-per-appointment model means no upfront marketing spend — you only pay when you see patients. Faster ramp-up (weeks instead of months), but you trade some autonomy for infrastructure support.

Next Steps: Building Your Telehealth ADHD Practice

If you’re a psychiatrist or PMHNP looking to leverage telehealth for ADHD care, here’s what to prioritize:

1. Verify your licensing and scope:

• Check that your medical license (or APRN license) is active and in good standing in states where you want to practice
• If you’re a PMHNP, confirm your state’s specific prescribing rules for Schedule II medications
• Consider strategic additional licenses in high-demand states

2. Ensure DEA and PDMP compliance:

• Obtain or renew your DEA registration (required for controlled substance prescribing)
• Register for PDMP access in every state where you’re licensed
• Familiarize yourself with state-specific PDMP checking requirements

3. Choose your practice model:

• DIY telehealth: Build your own patient acquisition (budget $3,000–5,000+/month for marketing, expect 6–12 month ramp-up)
• Join a platform: Start seeing patients within weeks, pay only per appointment, let the platform handle marketing and infrastructure

4. Set up clinical workflows:

• Select a DEA-compliant e-prescribing platform (if going solo) or confirm the platform you’re joining has one
• Create intake forms and ADHD rating scale workflows
• Develop documentation templates that ensure standard-of-care evaluations
• Plan for monthly follow-up scheduling (automate where possible)

5. Stay current on regulations:

• Monitor DEA announcements regarding telehealth controlled substance prescribing (critical for 2026)
• Join professional organizations (APA, AANP) that provide regulatory updates
• Review state medical board guidance periodically (telehealth rules are still evolving)

Why Klarity Health Makes Sense for ADHD Providers

If you’ve read this far, you understand the regulatory complexity, the patient acquisition economics, and the clinical workflows of telehealth ADHD care. You also know that building a sustainable practice requires solving multiple problems simultaneously: licensing, credentialing, marketing, technology, compliance, and billing.

Klarity Health removes the risk and the guesswork.

Instead of spending months and thousands of dollars testing marketing channels that may not work, you can start seeing pre-qualified ADHD patients within weeks. Instead of managing e-prescribing platforms, PDMP access, insurance credentialing, and billing systems separately, you get integrated infrastructure that just works.

The value proposition is simple:

• No upfront marketing spend or subscription fees
• Pay only when you see patients (guaranteed ROI)
• Pre-qualified patient flow matched to your specialty and availability
• Both insurance and cash-pay patients
• Built-in telehealth, e-prescribing, and compliance infrastructure
• You control your schedule and clinical decisions

For psychiatrists: You can practice independently across any states where you’re licensed, with full autonomy over treatment decisions.

For PMHNPs: In states requiring collaboration, Klarity can facilitate those physician partnerships. In full-practice states, you can operate independently just like an MD.

Whether you’re looking to supplement your current practice, transition fully to telehealth, or build a scalable ADHD-focused practice without the overhead of traditional brick-and-mortar, Klarity offers a proven path.

Ready to explore what your telehealth ADHD practice could look like?

Join Klarity’s provider network and start seeing patients without the marketing gamble — or schedule a conversation to discuss how the platform fits your specific practice goals and licensing situation.

Sources & References

The following sources were used to compile this guide. All regulatory and clinical information has been verified against official state statutes, federal agency guidance, and current medical literature as of February 2026.

Federal Regulations & Policy:

1. U.S. Drug Enforcement Administration & HHS – COVID-era telehealth controlled substance prescribing extended through Dec 31, 2025 – Axios, Nov 18, 2024
2. DEA Ryan Haight Act telehealth policy discussions – [Axios, Sept 18, 2024](https://www.axios.com/2024/09/18/telehealth-services

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the